SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 273 filers reported holding SAGE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $562,000 | -32.6% | 4,008 | -12.0% | 0.00% | -33.3% |
| Q2 2019 | $834,000 | +20.9% | 4,557 | +5.0% | 0.01% | 0.0% |
| Q1 2019 | $690,000 | +67.1% | 4,338 | +0.6% | 0.01% | +50.0% |
| Q4 2018 | $413,000 | -49.6% | 4,311 | -25.8% | 0.00% | -42.9% |
| Q3 2018 | $820,000 | -6.4% | 5,807 | +3.8% | 0.01% | -12.5% |
| Q2 2018 | $876,000 | +20.3% | 5,597 | +23.9% | 0.01% | +14.3% |
| Q1 2018 | $728,000 | +56.9% | 4,517 | +60.3% | 0.01% | +40.0% |
| Q4 2017 | $464,000 | +81.2% | 2,818 | -21.7% | 0.01% | +66.7% |
| Q1 2017 | $256,000 | – | 3,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |